Seattle startup HDT Bio will develop a nasal spray designed to counteract a wide range of respiratory viruses with a nearly $1.8 million grant from the U.S. Army. “We hope… Read More
An experimental COVID-19 vaccine in development by Seattle-based HDT Bio will enter early-stage clinical trials in the U.S., the company announced yesterday after the U.S. Food and Drug Administration cleared… Read More